Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Sponsor: Biotheus Inc.
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.
Official title: A Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Paclitaxel Injection as Second Line Treatment for Small Cell Lung Cancer(SCLC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
99
Start Date
2022-05-27
Completion Date
2026-04-30
Last Updated
2024-12-18
Healthy Volunteers
No
Conditions
Interventions
PM8002
IV infusion
Paclitaxel
IV infusion
Locations (11)
Peking University Cancer Hospital
Beijing, China
Jilin Provincial Tumor Hospital
Changchun, China
Hunan Cancer Hospital
Changsha, China
Sichuan Provincial People's Hospital
Chengdu, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Shandong Cancer Hospital
Jinan, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Shanghai Pulmonary Hospital
Shanghai, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Henan Cancer Hospital
Zhengzhou, China